Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19153010 | 0.75 | — | — | |
| SCHEMBL10077956 | 0.75 | — | — | |
| SCHEMBL31389647 | 0.69 | KDM4E (0.31) | KDM4EPKM | |
| SCHEMBL2347279 | 0.68 | ALDH1A1 (0.35) | KDM4EPKMALDH1A1MEN1LMNA | |
| SCHEMBL14437964 | 0.68 | CYP2A6 (0.32) | ALDH1A1HSD17B10 | |
| SCHEMBL12037021 | 0.67 | MAPT (0.33) | KDM4EPKMALDH1A1MEN1LMNA | |
| SCHEMBL14437974 | 0.67 | PI4KA (0.35) | — | |
| SCHEMBL14437971 | 0.67 | KDM4E (0.31) | KDM4EPKMALDH1A1MEN1LMNA | |
| SCHEMBL2444156 | 0.65 | — | — | |
| SCHEMBL12037215 | 0.64 | KDM4E (0.33) | KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-8809318-B2 | Gamma secretase modulators | MERCK SHARP & DOHME CORP. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8575166-B2 | Phthalazine-containing antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120004234-A1 | PHTHALAZINE-CONTAINING ANTIDIABETIC COMPOUNDS | SCHERING CORPORATION (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110306593-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME LLC | 2011-12-15 | — | — | US | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007022501-A2 | USEFUL INDOLE COMPOUNDS | MICROBIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004234-A1 | PHTHALAZINE-CONTAINING ANTIDIABETIC COMPOUNDS | GPR119, FFAR2, FFAR1 | KDM4E 2154/4885PKM 2822/4885ALDH1A1 3097/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | KDM4E 3060/4885PKM 413/4885ALDH1A1 2151/4885 |
| US-20110306593-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | KDM4E 2379/4885PKM 2223/4885ALDH1A1 3613/4885 |
| US-20070203209-A1 | Useful indole compounds | TPH2, HRH2, HRH1 | KDM4E 4314/4885PKM 4672/4885ALDH1A1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.